Rixan

Product name: Rixan
Generic name: Rivaroxaban
Dosage form: Oral tablets
Packaging: Box of 3 blisters of 10 tablets
Drug Category: Cardiovascular

Indications:

Rivaroxaban is a factor Xa inhibitor indicated::
to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
for the treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and for the reduction in the risk of recurrence of DVT and of PE
for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery

Dosage and Administration:

Nonvalvular Atrial Fibrillation:
1) For patients with CrCl >50 mL/min: 20 mg orally, once daily with the evening meal
2) For patients with CrCl 15 – 50 mL/min: 15 mg orally, once daily with the evening meal
Treatment of DVT, PE, and Reduction in the Risk of Recurrence of DVT and of PE:
15 mg orally twice daily with food for the first 21 days for the initial treatment of acute DVT or PE. After the initial treatment period, 20 mg orally once daily with food for the remaining treatment and the long-term reduction in the risk of recurrence of DVT and of PE
Prophylaxis of DVT Following Hip or Knee Replacement Surgery:
10 mg orally, once daily with or without food

Contraindication:

Hypersensitivity to the active substance or to any of the excipients.

Active clinically significant bleeding.

Lesion or condition, if considered to be a significant risk for major bleeding. This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial hemorrhage, known or suspected esophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities..  Concomitant treatment with any other anticoagulants, e.g. unfractionated heparin (UFH), low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, dabigatran etexilate, apixaban, etc.) except under specific circumstances of switching anticoagulant therapy or when UFH is given at doses necessary to maintain an open central venous or arterial catheter. Hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C. Pregnancy and breast-feeding.